L
105.62
2.30 (2.23%)
| 前收盘价格 | 103.32 |
| 收盘价格 | 104.90 |
| 成交量 | 128,798 |
| 平均成交量 (3个月) | 119,829 |
| 市值 | 2,036,459,264 |
| 预期市盈率 (P/E Forward) | 18.02 |
| 价格/销量 (P/S) | 12.02 |
| 股市价格/股市净资产 (P/B) | 2.55 |
| 52周波幅 | |
| 利润日期 | 8 May 2025 |
| 营业毛利率 | -2.41% |
| 营业利益率 (TTM) | 3.94% |
| 稀释每股收益 (EPS TTM) | -0.220 |
| 季度收入增长率 (YOY) | 52.40% |
| 总债务/股东权益 (D/E MRQ) | 0.86% |
| 流动比率 (MRQ) | 8.93 |
| 营业现金流 (OCF TTM) | 97.05 M |
| 杠杆自由现金流 (LFCF TTM) | 100.78 M |
| 资产报酬率 (ROA TTM) | 1.66% |
| 股东权益报酬率 (ROE TTM) | -0.53% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Ligand Pharmaceuticals Incorpor | 看跌 | 看涨 |
AIStockmoo 评分
1.4
| 分析师共识 | 1.5 |
| 内部交易活动 | NA |
| 价格波动 | 2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 2.0 |
| 平均 | 1.38 |
|
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 2.30% |
| 机构持股比例 | 98.15% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Villere St Denis J & Co /Adv | 31 Dec 2024 | 287,044 |
| 52周波幅 | ||
| 中 | 143.00 (35.39%) | |
| 总计 | 1 购买 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Stifel | 10 Apr 2025 | 143.00 (35.39%) | 购买 | 101.29 |
该时间范围内无数据。
| 日期 | 类型 | 细节 |
|---|---|---|
| 08 May 2025 | 公告 | Ligand Reports First Quarter 2025 Financial Results |
| 01 May 2025 | 公告 | Ligand to Participate in May Investor Conferences |
| 24 Apr 2025 | 公告 | Ligand to Report First Quarter 2025 Financial Results on May 8, 2025 |
| 17 Apr 2025 | 公告 | Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics |
| 03 Mar 2025 | 公告 | Ligand to Participate in March Investor Conferences |
| 27 Feb 2025 | 公告 | Ligand Reports Fourth Quarter and Full Year 2024 Financial Results |
| 25 Feb 2025 | 公告 | Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences |
| 13 Feb 2025 | 公告 | Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合